Drug Trial Radar · NCT03250325
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Sep 20, 2017
Primary completion
Jan 23, 2020
Study completion Mar 9, 2022
Sponsor
- Lead sponsor
- Takara Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.
Conditions
- Synovial Sarcoma
Interventions
TBI-1301Biological
Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
CyclophosphamideDrug
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Phase I) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test valuesTime frame: 52 weeks
- (Phase I) Appearance of replication competent retrovirus (RCR) by PCRTime frame: 52 weeks
- (Phase I) Appearance of clonality by linear amplification mediated (LAM)-PCRTime frame: 52 weeks
- (Phase I) Blood kinetics of TBI-1301 by realtime-PCRTime frame: 52 weeks
- (Phase II) Overall response rateTime frame: 52 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Kyushu University Hospital
Fukuoka, Japan
Sapporo Medical University Hospital
Sapporo, Hokkaido, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
National Hospital Organization Osaka National Hospital
Osaka, Osaka, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.